Sufferers often experience feelings of panic or extreme fear, similar to the fear they felt during the traumatic event.
Cannabis-focused healthcare company Bod Australia (ASX: BDA) has announced it will supply its pharmaceutical-grade cannabis extract MediCabilis for a landmark 12-month trial related to post traumatic stress disorder (PTSD).
It will be prescribed to 300 participants in oil form by Bod’s research partner Cannabis Access Clinics (CAC).
Patients will bear standard treatment costs for participating in the study, and will be eligible for rebates through Medicare or private insurance.
CAC has first-hand experience in PTSD treatment using medicinal cannabis and has previously reported positive effects of the drug on patient outcomes.
Specialist research organisation Applied Cannabis Research will assist with data collection and patient management.
The trial is expected to begin immediately.
Bod chief executive officer Jo Patterson said the intellectual property generated from the trial will be used to pursue product development, commercialisation and licencing opportunities for MediCabilis.
“We look forward to progressing this trial as it has the potential to significantly strengthen our revenue stream, as well as further validate our product suite,” she said.
“We will be pursuing similar agreements with medical organisations and research partners to replicate this model, further underpinning revenues from this trial and medical cannabis product sales for our pharma business.”
Source – Smallcaps
Image – ArmyAmber (p)
